Powder: -20°C for 3 years | In solvent: -80°C for 1 year
HSK0935 is a highly selective and orally available SGLT2 inhibitor (IC50: 1.3 nM). It has antihyperglycemic activities.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 326,000 |
50 mg | 約6-8 週間 | ¥ 424,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
ターゲット&IC50 | SGLT2:1.3 nM |
In vivo | In a 28-day repeat-dose toxicology study conducted on beagle dogs, HSK0935 was found to be well-tolerated at doses up to 300 mg/kg, without causing any deaths or severe adverse effects. Additionally, treatment with HSK0935 at doses of 1, 3, and 10 mg/kg resulted in significant urinary glucose excretion in Sprague-Dawley (SD) rats, and had an even greater effect on urinary glucose excretion in Rhesus monkeys[1]. |
別名 | HSK 0935, HSK-0935 |
分子量 | 436.88 |
分子式 | C22H25ClO7 |
CAS No. | 1638851-44-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
HSK0935 1638851-44-1 GPCR/G Protein SGLT HSK 0935 HSK-0935 Inhibitor inhibitor inhibit